Ten patients were recruited from outpatient psychiatry clinical settings at the University of New Mexico and Texas Tech University Schools of Medicine. Clinicians were asked to identify female patients, age 18 to 60 years, who provided oral informed consent, who were in stable relationships, who had normal premorbid sexual function, and who had developed sexual dysfunction, particularly anorgasmia, with or without other sexual disturbances (i.e., loss of libido, lubrication difficulties, uncomfortable or painful intercourse) while being effectively treated with a thymoleptic. The subjects had to be taking the antidepresssant for at least 6 weeks, currently receiving a stable dose and showing improvement of the presenting condition (usually depression, anxiety, or both), and experiencing sexual side effects continuously for more than 4 weeks. Exclusion criteria were concurrent unstable medical illness, poor overall physical health, history of sexual dysfunction (other than antidepressant-induced), psychiatric disorder not under control, previous or current alcohol or substance abuse or dependence, diabetes mellitus, neurological disorder, or genital anatomical defects. A history of stroke, myocardial infarction, or use or likely use of any nitrate caused a subject to be explicitly excluded. Treatment was provided in the context of the subjects’ ongoing clinical care and was approved by the hospital’s institutional review board.